Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, Beijing Shengdi Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”), received the “Notice of Acceptance” issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”). The company's application for a Class 1 innovative drug, coagulation factor XI (FXI) monoclonal antibody SHR-2004 injection was accepted by the State Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.